🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

32 results for “argenx” Clear

  1. Efgartigimod, ARGX-113

    argenx

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 2 small molecule active

    1 trial

  2. Placebo PH20 SC – prefilled syringe (placebo to Efgartigimod PH20 SC – prefilled syringe), Efgartigimod

    argenx

    Antibody-Mediated Rejection

    phase 2 small molecule active

    1 trial

  3. Placebo to ARGX-117 IV concentrate solution for infusion, ARGX-117

    argenx

    Myositis, Dermatomyositis

    phase 2 small molecule active

    1 trial

  4. Placebo to ARGX-117 IV, ARGX-117, ARGX-117

    argenx

    Multifocal Motor Neuropathy

    phase 2 small molecule active

    1 trial

  5. Placebo to ARGX-119 concentrate for solution for infusion, ARGX-119

    argenx

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  6. placebo PH20 SC PFS, Vyvgart 1 000 mg solution for injection in pre-filled syringe

    argenx

    Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  7. A study to assess the effects of efgartigimod on emasiprubart in healthy adult participants

    argenx

    not applicable

    phase 1 other active

    1 trial

  8. A study to assess the safety of ARGX-121 in Healthy Adult Participants

    argenx

    Healthy volunteers

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources